{"id":"W2205491921","doi":"10.1001/jama.2015.16669","title":"Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma","year":2015,"lang":"en","type":"article","venue":"JAMA","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1226,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Mundipharma EDO; Genentech; Novocure; Merck KGaA","keywords":"Temozolomide; Medicine; Interim analysis; Clinical endpoint; Population; Chemoradiotherapy; Oncology; Internal medicine; Progression-free survival; Clinical trial; Radiation therapy; Chemotherapy; Surgery","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}